Biosimilars approvals by thirteen regulatory authorities: A cross-national comparison13个监管机构批准的生物仿制药: 跨国比较REGULATORY TOXICOLOGY AND PHARMACOLOGYIF3.52023-10-012OAAI
What is happening with not recommended drugs for dementia in Argentina? Prescription patterns and direct costs analysisINTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRYIF2.82019-12-176PREAI
APPROVAL OF CANCER DRUGS EMA and FDA decisions based on flawed evidence to approve new cancer drugs negatively affect Latin American patientsBMJ-BRITISH MEDICAL JOURNALIF42.72019-10-155OAAI